Trial Profile
ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Alicaforsen (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics; Registrational
- Sponsors Ionis Pharmaceuticals
- 07 Jan 2016 New trial record